ChemoMetec (Denmark) Top Management
CHEMM Stock | DKK 473.60 6.40 1.33% |
ChemoMetec employs about 162 people. The company is managed by 20 executives with a total tenure of roughly 51 years, averaging almost 2.0 years of service per executive, having 8.1 employees per reported executive. Evaluation of ChemoMetec's management performance can provide insight into the firm performance.
Steen SoendergaardLarsen CEO Chief Executive Officer |
Claus Madsen CEO Acting Chief Executive Officer, Chief Financial Officer |
ChemoMetec |
ChemoMetec Management Team Effectiveness
The company has return on total asset (ROA) of 0.3117 % which means that it generated a profit of $0.3117 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.4858 %, meaning that it generated $0.4858 on every $100 dollars invested by stockholders. ChemoMetec's management efficiency ratios could be used to measure how well ChemoMetec manages its routine affairs as well as how well it operates its assets and liabilities.ChemoMetec Workforce Comparison
ChemoMetec AS is number one stock in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 436,917. ChemoMetec adds roughly 162 in number of employees claiming only tiny portion of equities under Health Care industry.
The company has Profit Margin (PM) of 0.39 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.5 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.5. ChemoMetec AS Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. ChemoMetec AS Price Series Summation is a cross summation of ChemoMetec price series and its benchmark/peer.
ChemoMetec Notable Stakeholders
A ChemoMetec stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as ChemoMetec often face trade-offs trying to please all of them. ChemoMetec's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting ChemoMetec's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Steen SoendergaardLarsen | Chief Executive Officer | Profile | |
Claus Madsen | Acting Chief Executive Officer, Chief Financial Officer | Profile | |
Hans Glensbjerg | Vice Chairman of The Board, COO and Director | Profile | |
Preben Koenig | Chairman of the Board | Profile | |
Martin Glensbjerg | Vice Chairman of the Board, Chief Operating Officer | Profile | |
Nils Isbak | Vice President Global Sales | Profile | |
Peter Reich | Independent Director | Profile | |
Christian Berg | Product Manager | Profile | |
Kurt Nielsen | Production and Procurement Manager | Profile | |
Michael Packert | Head of Production | Profile | |
Kristine Faerch | Director | Profile | |
Martin Behrens | Chief US | Profile | |
Christopher MSc | VP US | Profile | |
Soeren Kjaerulff | Head of Research & Development | Profile | |
Steen Sondergaard | Chief Officer | Profile | |
Lisbet Helles | Head of Marketing | Profile | |
Sren Kjrulff | Head RD | Profile | |
Niels Nielsen | Chief Officer | Profile | |
Louise Petersen | Quality Manager | Profile | |
Christopher Runchel | Senior Vice President - United States | Profile |
About ChemoMetec Management Performance
The success or failure of an entity such as ChemoMetec AS often depends on how effective the management is. ChemoMetec management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of ChemoMetec management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the ChemoMetec management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
ChemoMetec AS engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company was founded in 1997 and is headquartered in Allerd, Denmark. ChemoMetec operates under Medical Equipment classification in Denmark and is traded on Copenhagen Stock Exchange. It employs 155 people.
Please note, the presentation of ChemoMetec's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, ChemoMetec's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of ChemoMetec's management manipulating its earnings.
ChemoMetec Workforce Analysis
Traditionally, organizations such as ChemoMetec use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare ChemoMetec within its industry.ChemoMetec Manpower Efficiency
Return on ChemoMetec Manpower
Revenue Per Employee | 2.6M | |
Revenue Per Executive | 21.4M | |
Net Income Per Employee | 984.4K | |
Net Income Per Executive | 8M | |
Working Capital Per Employee | 154.3K | |
Working Capital Per Executive | 1.2M |
Complementary Tools for ChemoMetec Stock analysis
When running ChemoMetec's price analysis, check to measure ChemoMetec's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ChemoMetec is operating at the current time. Most of ChemoMetec's value examination focuses on studying past and present price action to predict the probability of ChemoMetec's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ChemoMetec's price. Additionally, you may evaluate how the addition of ChemoMetec to your portfolios can decrease your overall portfolio volatility.
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Stocks Directory Find actively traded stocks across global markets | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |